REMARKS

Imposed Restriction Requirement

In the Office Action dated November 30, 2009, the Office imposed a restriction requirement under 35 U.S.C. §121 against the pending claims and requested applicants choose a species as set forth below recreated from the text of the office action:

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The species are as follows:

azo-bonded 4-APAA compounds;

non-azo-bonded 4-APAA compounds;

azo-bonded 5-ASA compounds;

non-azo-bonded 5-ASA compounds; and

4-APAA compounds azo-bonded to 5-ASA compounds.

Initially it should be noted that applicants' invention must include a first and second therapeutic compound to form the claimed composition, as shown below:

- 1. A pharmaceutical composition comprising:
- a first therapeutic agent selected from the group consisting of:

azo-bonded 4-APAA compound; non-azo bonded 4-APAA compound; azo-bonded 5-ASA compound; non-azo bonded 5-ASA compound; and

a second therapeutic agent comprising a

4-APAA compound azo bonded to a 5-ASA compound.

Thus applicants must pick two from the above list that being

- 1. non-azo bonded 4-APAA compound; and
- 2. 4-APAA compounds azo-bonded to 5-ASA compounds.

The structure for the 4-APAA compounds azo-bonded to 5-ASA compound is as follows:

The non-azo bonded 4-APAA compound has the following structure:

The above compound are covered within the scope of claim 1-9, 15 and 30.

If any issues remain outstanding incident to the allowance of the application, Examiner Spivack is requested to contact the undersigned attorney at (919) 286-8089.

Respectfully submitted,

Marianne Fuierer Attorney for Applicant

Registration No. 39,983

Moore & Van Allen PLLC P. O. Box 13706 Research Triangle Park, NC 27709 Telephone: (919) 286-8000 Facsimile: (919) 286-8199

Attorney Docket No. 014811-673.119US